UGNE - Oversold with an Improving RSI Alert
Posted by: GCM / Category: Oversold / Improving RSIUnigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use. It focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). The company offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis; and Forcaltonin, an injectable calcitonin product for the treatment of Paget’s disease and hypercalcemia. It markets Fortical in the United States, and Forcaltonin in Europe. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; with Upsher-Smith Laboratories, Inc. to market Fortical; and with Novartis to manufacture calcitonin.
UGNE at 9:55 AM 10/15/2008: Oversold with an Improving RSI
